Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Genocea Biosciences Inc    GNCA

GENOCEA BIOSCIENCES INC

(GNCA)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

GENOCEA BIOSCIENCES, INC. : Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 08:40am EST

Item 3.02 Unregistered Sales of Equity Securities.

To the extent required by Item 3.02 of Form 8-K, the information regarding the Common Stock and Warrants set forth under Item 1.01 of this Form 8-K is incorporated by reference in this Item 3.02. The Company issued the Common Stock and Warrants in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The Company relied on this exemption from registration for private placements based in part on the representations made by the Purchasers, including the representations with respect to each Purchaser's status as an accredited investor, as such term is defined in Rule 501(a) of the Securities Act, and each Purchaser's investment intent.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

4.1    Form of Pre-Funded Warrant
4.2    Form of Warrant
99.1   Press Release, dated February 12, 2019

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENOCEA BIOSCIENCES INC
02/12GENOCEA BIOSCIENCES, INC. : Unregistered Sale of Equity Securities, Financial St..
AQ
02/12Genocea Announces Private Placement Financing of Up to $39 Million
GL
01/07GENOCEA BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and E..
AQ
01/02Genocea Doses First Patients and Completes Enrollment in Part A of Phase 1/2a..
GL
2018GENOCEA BIOSCIENCES, INC. : Notice of Delisting or Failure to Satisfy a Continue..
AQ
2018Genocea Appoints Girish Aakalu, Ph.D., Chief Business Officer
GL
2018Genocea To Host a Key Opinion Leader Event November 26th on Latest Advances i..
GL
2018GENOCEA BIOSCIENCES : Unveils Possible Mechanism for Tumor Resistance to Immunot..
PU
2018Genocea Unveils Possible Mechanism for Tumor Resistance to Immunotherapy at ..
GL
2018GENOCEA BIOSCIENCES : Management's Discussion and Analysis of Financial Conditio..
AQ
More news